Myelodysplastic syndrome (mds) with isolated del(5q)

Abstract

Myelodysplastic syndrome (MDS) with isolated del(5q) is characterized by anemia, hypolobated megacaryocytes, < 5% bone marrow blast, the del(5q) cytogenetic abnormality and a good prognosis. Here, we have analyzed the clinical, prognostic and therapeutic data from cases diagnosed over the last 10 years at the Donostia University Hospital. The use of lenalidomide as treatment had many side effects in addition to positive ones, indicating that patient selection to use this drug should be carried out carefully. A treatment protocol is proposed in order to do so.